ライフサイエンスコーパス: oral contraceptive

1 of hypertension, smoking status, and use of oral contraceptives.

2 sociation was found in women who did not use oral contraceptives.

3 effectively reduce the symptoms, as can some oral contraceptives.

4 -mass index, alcohol consumption, and use of oral contraceptives.

5 ity may reduce the biologic effectiveness of oral contraceptives.

6 s conceptions that occurred while women used oral contraceptives.

7 cation of polyps after the administration of oral contraceptives.

8 rofiles versus currently available steroidal oral contraceptives.

9 nd it may be limited to women who do not use oral contraceptives.

10 s that address adherence problems noted with oral contraceptives.

11 e similar for women who did and did not take oral contraceptives.

12 ast cancer among former and current users of oral contraceptives.

13 strong risk factor for CVT in women who use oral contraceptives.

14 esidence, low body mass index, and no use of oral contraceptives.

15 race/ethnicity, employment, and prior use of oral contraceptives.

16 those reported in young women who are taking oral contraceptives.

17 ant's mother, age at hysterectomy, or use of oral contraceptives.

18 ne contraception; most counseling focused on oral contraceptives.

19 .1; Pheterogeneity compared with using other oral contraceptives = 0.004) was associated with particu

20 ) metformin vs placebo or estrogen-progestin oral contraceptives, (3) insulin-sensitizing agents, and

21 sed Depo-Provera, patch, or ring; 22.4% used oral contraceptives; 40.8% used condoms; 11.8% used with

22 s (75%), contraceptive injections (57%), and oral contraceptives (51%).

23 lare, occurred in 7 of 91 subjects receiving oral contraceptives (7.7 percent) as compared with 7 of

24 33 [71.5%] vs 3220 [52.5%]), more often used oral contraceptives (97 [72.9%] vs 758 [23.5%] of women)

25 May 1, 1968, and July 31, 1974, who had used oral contraceptives, a diaphragm, or an intrauterine dev

26 Oral contraceptives (adjusted relative risk [RR], 2.02 [

27 A, and the wide-spread clinical use of EE as oral contraceptive adjuvant, the impact of these estroge

28 were similar: 0.084 for the group receiving oral contraceptives and 0.087 for the placebo group (P=0

29 8 to 1.3) for women who were currently using oral contraceptives and 0.9 (95 percent confidence inter

30 lares per person-year for subjects receiving oral contraceptives and 1.44 flares per person-year for

31 Previous studies of oral contraceptives and breast cancer indicate that rece

32 , particularly in relation to the effects of oral contraceptives and changes in sexual behaviour.

33 ical cancer is increased in current users of oral contraceptives and declines after use ceases.

34 atic cancer for users of exogenous hormones (oral contraceptives and ERT), results did not show a con

35 n women with migraine who are using combined oral contraceptives and have additional risk factors tha

36 Both oral contraceptives and hormonal therapy for menopause c

37 y, income, body mass index, diabetes, use of oral contraceptives and hormone replacement therapy amon

38 risk is now clarified: current users of both oral contraceptives and hormone replacement therapy expe

39 ity, number of full-term pregnancies, use of oral contraceptives and hormone replacement therapy, and

40 ment of women who had migraine with combined oral contraceptives and hormone replacement therapy, as

41 and are influenced by the administration of oral contraceptives and hormone replacement therapy.

42 eased with age, income, and long-term use of oral contraceptives and increased with number of sexual

43 After adjustment for oral contraceptives and other factors, current smokers w

44 Oral contraceptives and pregnancies had a significantly

45 a statistical association between the use of oral contraceptives and return of menstrual cycle, which

46 A similar debate about oral contraceptives and stroke risk in young women conti

47 und between premenopausal volunteers free of oral contraceptives and those who used oral contraceptiv

48 hanges in nevi during pregnancy, while using oral contraceptives and/or hormone replacement therapy.

49 ) LARC (intrauterine device or implant), (2) oral contraceptives, and (3) Depo-Provera, patch, or rin

50 ad regular menstrual cycles, were not taking oral contraceptives, and had not breastfed or been pregn

51 atural menopause, while parity, prior use of oral contraceptives, and Japanese race/ethnicity were as

52 che and menopause, menopausal status, use of oral contraceptives, and menopausal hormone therapy) and

53 duration of corticosteroid use, less use of oral contraceptives, and menopause status.

54 ion of use of hormone replacement therapy or oral contraceptives, and no association with previous us

55 R was slightly stronger among women who used oral contraceptives, and the association remained null i

56 ug interactions, however, in patients taking oral contraceptives, antivirals, or immunosuppressants.

57 Combined oral contraceptives are classified by the International

58 Although oral contraceptives are protective for ovarian cancer, i

59 Oral contraceptives are rarely prescribed for women with

60 Although most women using oral contraceptives are reliably protected against pregn

61 data have provided further reassurance that oral contraceptives are safe for patients who have had m

62 Oral contraceptives are the most popular reversible meth

63 The role of vitamin D and oral contraceptives as modifiers of disease risk remains

64 e each year approximately 3% of women taking oral contraceptives become pregnant.

65 No association was found for use of oral contraceptives before or during pregnancy (first tr

66 Intake of oral contraceptives (beta, 0.150; 95% CI, 0.0649 to 0.23

67 Tamoxifen, oral contraceptives, bilateral salpingo-oophorectomy, ma

68 viral types increased with parity and use of oral contraceptives but not with injectable progestogens

69 (12% of the total) seemed little affected by oral contraceptives, but otherwise the proportional risk

70 Use of oral contraceptives by women with a family history of br

71 Treatment with combined oral contraceptives can help women with acne.

72 Oral contraceptives can reduce the risk of ovarian cance

73 Short-acting contraception methods (eg, oral contraceptives) can be used as a temporary bridge t

74 Among users of low-dose oral contraceptives, cardiovascular diseases occur mainl

75 raceptives and combined estrogen/progestogen oral contraceptives (COCs) may increase the risk of brea

76 nce of HIV infection in women using combined oral contraceptives (COCs) or the injectable progestins

77 rding to sexual activity and use of combined oral contraceptives (COCs), with highest rates reported

78 ger duration and more recent use of combined oral contraceptives (COCs).

79 Current treatments include oral contraceptives combined with nonsteroidal anti-infl

80 Use of oral contraceptives confers long-term protection against

81 the subgroups of women starting combination oral contraceptives containing both estrogen and progest

82 abolism of various drugs, including combined oral contraceptives, cyclosporin, and indinavir.

83 Our study indicates that oral contraceptives do not increase the risk of flare am

84 t (P = .0065), and in women who did not take oral contraceptives during chemotherapy (P = .0002).

85 rrhea: age, treatment, stage, and the use of oral contraceptives during chemotherapy.

86 The women reported whether they took oral contraceptives during their teens, twenties, and th

87 usual menstrual cycle length when not using oral contraceptives during these decades.

88 besity plays a biologically relevant role in oral contraceptive effectiveness.

89 ential triggers included estrogen-containing oral contraceptives (eOC), hormonal replacement therapy,

90 Oral contraceptive estrogen and progestin content were c

91 = 30 vs. 18.5-24.9) had an increased risk of oral contraceptive failure (hazard ratio = 1.59, 95% con

92 to further investigate the potential obesity-oral contraceptive failure association using 2002 Nation

93 ) was derived from self-reported values, and oral contraceptive failure was defined as conceptions th

94 udy found no association between obesity and oral contraceptive failure.

95 However, for women using oral contraceptives for >5 years, the rate ratio for ova

96 ts with CD receiving the combination type of oral contraceptives for at least 1 year, 1 extra surgery

97 Women take oral contraceptives for contraception but also for menst

98 following the development of hormonal-based oral contraceptives for women has had a major impact on

99 ases and 32,717 (37%) controls had ever used oral contraceptives, for average durations among users o

100 eported use and did not examine contemporary oral contraceptive formulations.

101 10 years' use of oral contraceptives from around age 20 to 30 years is es

102 omen and women who reported ever having used oral contraceptives had a decreased risk of glioma.

103 Current use of oral contraceptives had a significantly protective effec

104 ents (age range, 15-19 years) using combined oral contraceptives had an RR of a first use of an antid

105 Compared with nonusers, users of combined oral contraceptives had an RR of first use of an antidep

106 Women who had ever used oral contraceptives had increased mortality from cervica

107 Current users of oral contraceptives had poorer periodontal health.

108 Women who had used oral contraceptives had significantly lower risk of inte

109 Oral contraceptives had some adverse effect on deaths fr

110 the persistence of effects long after use of oral contraceptives has ceased.

111 These findings suggest that oral contraceptives have already prevented some 200,000

112 n, and pack-years), alcohol, family history, oral contraceptive, hormones, physical activity, and die

113 for thrombosis, such as advanced age, use of oral contraceptives, hyperhomocystinemia, and deficienci

114 to 2 clinical studies and found to act as an oral contraceptive in combination with a progestin, with

115 CC is evident in young noncirrhotic users of oral contraceptives in the United States and Europe.

116 This paper addresses the use of combined oral contraceptives in women older than 35 years of age,

117 There is no contraindication to the use of oral contraceptives in women with migraine in the absenc

118 ity, use of hormone replacement therapy, and oral contraceptives in women.

119 tion, the RR estimates for users of combined oral contraceptives increased to 1.7 (95% CI, 1.66-1.71)

120 It is uncertain whether the use of an oral contraceptive increases the risk of breast cancer l

121 Recent use of oral contraceptives involving high-dose estrogen (OR, 2.

122 ults suggest that recent use of contemporary oral contraceptives is associated with an increased brea

123 nylestradiol (EE2), a synthetic oestrogen in oral contraceptives, is one of many pharmaceuticals foun

124 The results also suggest that oral contraceptives may alter the effects of caffeine on

125 - to 2.0-fold increased risk; current use of oral contraceptives, nulliparity, and age 30 years or ol

126 Oral contraceptive (OC) pills are effective, but poor co

127 revious findings on the associations between oral contraceptive (OC) use and reproductive factors and

128 We evaluated the associations of oral contraceptive (OC) use and reproductive factors wit

129 Oral contraceptive (OC) use has been consistently linked

130 Oral contraceptive (OC) use has been linked to increased

131 The relationship between ischemic stroke and oral contraceptive (OC) use has been studied for 40 year

132 ater during the "high-hormone" phase (HH) of oral contraceptive (OC) use in 9 women.

133 Oral contraceptive (OC) use increased with time since mi

134 Oral contraceptive (OC) use is weakly associated with br

135 ng women and how these risks are affected by oral contraceptive (OC) use.

136 Total IgA and IgG levels were higher among oral contraceptive (OC) users than among naturally cycli

137 Oral contraceptives (OC) have historically been consider

138 Whether use of combined oral contraceptives (OC) protects against benign ovarian

139 ence suggests that use of high-dose combined oral contraceptives (OCs) (containing >50 microg of estr

140 Oral contraceptives (OCs) affect the risk of several can

141 The supremacy of combined oral contraceptives (OCs) is being challenged.

142 Use of oral contraceptives (OCs) may prevent the development of

143 tatus can occur in a subset of women who use oral contraceptives (OCs) with uncertain metabolic conse

144 eptive hormones, most commonly prescribed as oral contraceptives (OCs), are a widely utilized method

145 Use of exogenous hormones, in the form of oral contraceptives (OCs), has been linked consistently

146 ity to be exposed, such as men in studies on oral contraceptives (OCs).

147 reduced risk was associated with ever use of oral contraceptives (odds ratio = 0.54 (95% confidence i

148 al, we prospectively evaluated the effect of oral contraceptives on lupus activity in premenopausal w

149 esults suggest that the beneficial effect of oral contraceptives on ovarian cancer risk attenuates af

150 counsel about LARC even before suggesting an oral contraceptive or another less effective contracepti

151 sociated with PMS was not modified by use of oral contraceptives or antidepressants but was attenuate

152 males but not for females after exposure to oral contraceptives or clomiphene.

153 er was stronger for women who had never used oral contraceptives or ERT (odds ratio = 11.5, 95% confi

154 colorectal cancer is reduced among users of oral contraceptives or menopausal hormone therapy, but a

155 e observation in women that long-term use of oral contraceptives or multiple pregnancies significantl

156 , which can be managed with short courses of oral contraceptives or nonsteroidal anti-inflammatory dr

157 rdiovascular disease; or history of aspirin, oral contraceptive, or hormone replacement therapy.

158 en during pregnancy, after administration of oral contraceptives, or during postmenopausal replacemen

159 atification revealed that, in women who used oral contraceptives, overweight and obesity were associa

160 ee of oral contraceptives and those who used oral contraceptives (P = .28-0.82) and between premenopa

161 y, diet, smoking, alcohol intake, and use of oral contraceptives (per 1-unit increase in BMI, mean di

162 Whether other factors such as diet, oral contraceptives, perinatal/childhood infections, or

163 l and international debate occurred when the oral contraceptive pill ("the Pill" or "OCP") was approv

164 ed hazard ratio [aHR], 0.6; 95% CI, .4-1.2), oral contraceptive pill (aHR, 0.8; 95% CI, .3-2.1), nor

165 t completely resolved after cessation of the oral contraceptive pill (OCP) and associated adenoma reg

166 amine the associations between sex hormones, oral contraceptive pill (OCP) use, systemic inflammation

167 interaction effects on risk existed between oral contraceptive pill use or pregnancy and family hist

168 Among anovulation factors, prolonged oral contraceptive pill use provided a greater protectiv

169 tivity attenuated the inverse association of oral contraceptive pill use with risk.

170 ohol, but not for diabetes mellitus, cancer, oral contraceptive pill use, surgical menopause, hormone

171 n premenopausal females were not matched for oral contraceptive pill use.

172 ied with sex and 66 molecules varied between oral contraceptive pill users, postmenopausal females, a

173 gnosis, smoking history, or prior use of the oral contraceptive pill.

174 asing intrauterine device (LNG-IUD; n = 27), oral contraceptive pills (n = 32), or no hormonal contra

175 Oral contraceptive pills (OCPs) have been associated wit

176 e of an increased HIV risk in ten studies of oral contraceptive pills (pooled HR 1.00, 0.86-1.16) or

177 City, New York, USA) and, perhaps, low-dose oral contraceptive pills can have adverse effects on ado

178 lipidaemia, lipid profile, parity and use of oral contraceptive pills in females, smoking and alcohol

179 The use of combined hormonal oral contraceptive pills is a well-known acquired risk f

180 men for factor V Leiden prior to prescribing oral contraceptive pills is not a cost-effective use of

181 Most of the studies that assessed the use of oral contraceptive pills showed no significant associati

182 Use of oral contraceptive pills was protective.

183 quisition", "injectables", "progestin", and "oral contraceptive pills".

184 r commonly prescribed contraceptive methods (oral contraceptive pills, transdermal patch, contracepti

185 o carry the factor V Leiden mutation and use oral contraceptive pills.

186 tables, and seven also reported findings for oral contraceptive pills.

187 In contrast, ethynyl beta-estradiol (an oral contraceptive) potentiates both human and rat alpha

188 Factors that induced anovulation, including oral contraceptives, pregnancy, and breastfeeding, were

189 Since the patient was taking oral contraceptives prior to the onset of the lesion, a

190 Increased use of oral contraceptives soon after migration to the United S

191 re common in women than men, and exposure to oral contraceptive steroids and conjugated estrogens inc

192 the stimulation of lamotrigine metabolism by oral contraceptive steroids and the inhibition of carbam

193 robial, and cardiovascular drugs, as well as oral contraceptive steroids.

194 As compared with nonuse, current use of oral contraceptives that included ethinyl estradiol at a

195 was increased by a factor of 0.9 to 1.7 with oral contraceptives that included ethinyl estradiol at a

196 Among current users of oral contraceptives the risk of invasive cervical cancer

197 The longer that women had used oral contraceptives, the greater the reduction in ovaria

198 rol for age, smoking status, and past use of oral contraceptives, the median time to menopause increa

199 In the group that was randomized to receive oral contraceptives, there was one deep venous thrombosi

200 Prescribed oral contraceptives to regulate her menses and help redu

201 tes were randomly assigned to receive either oral contraceptives (triphasic ethinyl estradiol at a do

202 breast cancer risk associated with different oral contraceptive types could impact discussions weighi

203 d from time to pregnancy studies may now use oral contraceptives until they plan a pregnancy later in

204 A longer duration of oral contraceptive use (>/=10 years of use compared with

205 ; 95% confidence interval [CI], 1.69-10.30), oral contraceptive use (AOR, 2.78; 95% CI, 1.04-7.48), a

206 (P for trend = 0.02) and increasing years of oral contraceptive use (P for trend = 0.02).

207 , 95% confidence interval [95% CI] 1.4-3.2), oral contraceptive use (pooled RR 1.5, 95% CI 1.1-2.1),

208 I: 0.41, 0.73) for noncarriers), duration of oral contraceptive use (risk reduction per year = 13% (p

209 Recent oral contraceptive use (within the prior year) was assoc

210 isk significantly decreased with duration of oral contraceptive use [per five-year increments OR ESR2

211 re this, the authors examined the history of oral contraceptive use among 1322 Black women and White

212 Current oral contraceptive use and elective abortion were not as

213 Oral contraceptive use and hormone replacement therapy w

214 study, we compared mortality in relation to oral contraceptive use and smoking to highlight the diff

215 at first livebirth, waist-to-hip ratio, and oral contraceptive use did not differ by hormone recepto

216 story of menorrhagia, which was managed with oral contraceptive use for 20 years; this was stopped in

217 for age, sex, race, parental education, and oral contraceptive use found a significant positive rela

218 risk persisted for more than 30 years after oral contraceptive use had ceased but became somewhat at

219 Oral contraceptive use increases risk for venous thrombo

220 Oral contraceptive use indicated a lower risk of all NHL

221 Detailed oral contraceptive use information was ascertained from

222 There was no harmful effect of oral contraceptive use on overall mortality.

223 MH use or duration, time since last PMH use, oral contraceptive use or duration, age at menarche, age

224 variables measured included age, race, prior oral contraceptive use or progesterone treatment, prior

225 The prevalence of oral contraceptive use strictly for medical problems was

226 ssociations of HPV with recent pregnancy and oral contraceptive use suggest that hormonal factors may

227 univariate analysis found HIV infection and oral contraceptive use to be associated with the amount

228 served associations with age at menarche and oral contraceptive use warrant further investigation.

229 lative risk of ovarian cancer in relation to oral contraceptive use was estimated, stratifying by stu

230 Duration of oral contraceptive use was inversely associated with ris

231 increasing parity and increasing duration of oral contraceptive use were associated with decreased ri

232 origin, study site, parity, and duration of oral contraceptive use were included in all analytical m

233 Higher educational level, prior oral contraceptive use, and higher weight at baseline, a

234 Conversely, breastfeeding, oral contraceptive use, and late age at first pregnancy

235 le fractions associated with tubal ligation, oral contraceptive use, and obesity were markedly higher

236 ng studies with adjustment for smoking, BMI, oral contraceptive use, and parity, compared to studies

237 Smoking, oral contraceptive use, and report of a new male sex par

238 years, age at menarche, age at first birth, oral contraceptive use, bilateral oophorectomy, estrogen

239 uration of breastfeeding, menopausal status, oral contraceptive use, body mass index, and the time be

240 modeling, with adjustment for age, smoking, oral contraceptive use, body mass index, menopausal stat

241 Parity, oral contraceptive use, cigarette smoking, age at menarc

242 Early age at menarche, oral contraceptive use, early age at menopause, surgical

243 n was found between age at menarche, parity, oral contraceptive use, estrogen replacement therapy (ER

244 alyses adjusted for age, menopause type, and oral contraceptive use, ever use of estrogen only was si

245 parity/age at first birth, age at menarche, oral contraceptive use, family history of breast or ovar

246 a questionnaire obtaining information about oral contraceptive use, hormone replacement therapy, rep

247 vity, smoking, physical activity, menopause, oral contraceptive use, hormone therapy, and field cente

248 varian cancer were observed with duration of oral contraceptive use, later age at last use, and more

249 usal status, age at menopause, BMI, smoking, oral contraceptive use, MHT use, and an interaction term

250 BMI and MHT use; the ovarian model included oral contraceptive use, MHT use, and family history or b

251 ups resembled each other closely in terms of oral contraceptive use, nulliparity, and religion and di

252 the strongest risk predictors, pregnancy and oral contraceptive use, occur in most women in their twe

253 ly affected by phase of the menstrual cycle, oral contraceptive use, or early pregnancy.

254 ved with age at menarche, parity, lactation, oral contraceptive use, or female hormone use.

255 ndently influenced by menstrual cycle phase, oral contraceptive use, or plasma estradiol level.

256 ed whether postmenopausal hormone (PMH) use, oral contraceptive use, parity, and other reproductive f

257 weight, waist circumference, alcohol intake, oral contraceptive use, physical activity, short pregnan

258 Age at menarche, oral contraceptive use, pregnancy, parity, age at first

259 radox can be broadened (ie, the risk factors oral contraceptive use, pregnancy, puerperium, minor leg

260 2.75; P = 0.003), adjusted for age, parity, oral contraceptive use, site of study, and family histor

261 oup for the modifiable factors of pregnancy, oral contraceptive use, tubal ligation, and body mass in

262 ian cancer risk is inversely associated with oral contraceptive use, tubal ligation, and childbearing

263 have similar risk reductions associated with oral contraceptive use, tubal ligation, and parity.

264 rying degrees, smoking, alcohol consumption, oral contraceptive use, vasectomy and induced abortion a

265 birth year and adjusted for age, parity, and oral contraceptive use, we assessed associations for all

266 ppressing ovulation, including pregnancy and oral contraceptive use, were inversely associated with t

267 on between cervical carcinoma and pattern of oral contraceptive use.

268 ake, multivitamin use, menopausal status, or oral contraceptive use.

269 nobese group (P < 0.05) after adjustment for oral contraceptive use.

270 ng number of livebirths and with duration of oral contraceptive use.

271 , age at menarche, number of livebirths, and oral contraceptive use.

272 ry of cancer, ethnicity, smoking status, and oral contraceptive use.

273 sed treatment of subfertility, or changes in oral contraceptive use.

274 of breast cancer, nor was the initiation of oral-contraceptive use at a young age.

275 rom 35 to 64 years of age, current or former oral-contraceptive use was not associated with a signifi

276 0 micromol/liter, 95% CI: 5.4, 6.8), but not oral contraceptive users (7.9 micromol/liter, 95% CI: 7.

277 60% less likely to use condoms compared with oral contraceptive users (adjusted prevalence ratio [aPR

278 or more recent sexual partners compared with oral contraceptive users (aPR, 2.61; 95% CI, 1.75-3.90)

279 cycle (n=30) or the pseudo luteal phase for oral contraceptive users (n=32).

280 ed in analyses of menstrual function because oral contraceptive users are excluded.

281 of cycle characteristics caused by excluding oral contraceptive users from analyses of menstrual func

282 than those of comparably aged men, and most oral contraceptive users had plasma PLP < 20 nmol/L.

283 isk of ovarian cancer was reduced by 40% for oral contraceptive users overall, with longer duration o

284 Analyses limited to oral contraceptive users showed that duration was a more

285 k, regardless of tumor aggressiveness, while oral contraceptive users were at decreased risk of only

286 periportal location is specifically found in oral contraceptive users, associated with an inflammator

287 non-Hispanic blacks, and current and former oral contraceptive users.

288 it had little effect on melatonin levels for oral contraceptive users.

289 intercourse without one and (2) among female oral-contraceptive users than among sexually active nonu

290 cysteine concentration than nonpregnant, non-oral-contraceptive-using women (8.1 micromol/liter, 95%

291 rate ratio for death in women who ever used oral contraceptives was 0.89 (95% CI 0.77-1.02).

292 Registry of Ireland revealed that the use of oral contraceptives was associated with a decreased need

293 Having used oral contraceptives was associated with a lower risk of

294 In high-income countries, 10 years use of oral contraceptives was estimated to reduce ovarian canc

295 creening women prior to prescribing combined oral contraceptives was the least cost-effective strateg

296 Oral contraceptives were introduced almost 50 years ago,

297 rations, and the proportion of females using oral contraceptives were similar in the 2 groups.

298 eas other types, including low-dose estrogen oral contraceptives, were not (OR, 1.0; 95% CI, 0.6-1.7)

299 Although past studies have shown that oral contraceptives with 50 microg or more of estrogen r

300 s a synthetic progestin increasingly used in oral contraceptives with similar effects to progesterone